Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04500665 · ClinicalTrials.gov registry record · Phase 2
Anti-Inflammatory Treatment of Uremic Cardiomyopathy With Colchicine
A Phase 2 study of Chronic Kidney Diseases, sponsored by Brigham and Women's Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04500665: Recruiting Phase 2 study of Chronic Kidney Diseases, sponsored by Brigham and Women's Hospital.
NCT04500665 is a Phase 2 study of Chronic Kidney Diseases that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 20 participants, below the 445-participant average among 73 other Chronic Kidney Diseases trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04500665, a Phase 2 study of Chronic Kidney Diseases, is actively recruiting participants, sponsored by Brigham and Women's Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to determine the efficacy and safety of colchicine in patients with chronic kidney disease.
Primary Outcome
Assessed using transthoracic echocardiography
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Colchicine
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-11-01 |
| Est. Completion | 2026-11-11 |
| Phase | Phase 2 |
What NCT04500665 shows while recruiting
NCT04500665 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 445-participant average among 73 other Chronic Kidney Diseases trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Chronic Kidney Diseases appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04500665 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04500665 about?
NCT04500665 is a clinical study titled "Anti-Inflammatory Treatment of Uremic Cardiomyopathy With Colchicine". This study is designed to determine the efficacy and safety of colchicine in patients with chronic kidney disease.
What is the current status of trial NCT04500665?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2021-11-01. Estimated completion is 2026-11-11.
What conditions does trial NCT04500665 study?
This clinical trial studies the following conditions: Chronic Kidney Diseases.
What interventions are being tested in trial NCT04500665?
The interventions under investigation include: Placebo (DRUG), Colchicine (DRUG).
Who is sponsoring clinical trial NCT04500665?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04500665 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04500665's enrollment target sits among peer trials
20 69th of 73 higher than 4 of 73 other Chronic Kidney Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Kidney Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
RECRUITING · Phase 2
-
Ferric Citrate and Chronic Kidney Disease in Children
RECRUITING · Phase 2
-
Bone in CKD Alkali Response (BICARb Pilot Trial)
RECRUITING · Phase 2
-
Combination of Novel Therapies for CKD Comorbid Depression
RECRUITING · Phase 2
-
Acute Equol Supplementation and Vascular Function in Women With and Without CKD
RECRUITING · Phase 2
-
Sit Less, Interact and Move More (SLIMM) 2 Study
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI